Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and the third leading cause of cancer deaths worldwide. Risk factors include hepatitis and excessive alcohol use. Complete surgical resection or liver transplantation offers the best outcomes for eligible patients with early-stage HCC. For patients who cannot undergo surgery, radiofrequency ablation and chemoembolization provide good local control of small, localized tumors. Systemic therapies are minimally effective for HCC due to resistance, and palliation is the main goal for widespread disease. Long-term survival requires a multidisciplinary approach and close monitoring for recurrence.
Author: Dr Christa Maria Joel
Module: Effects of lifestyle on health
Supervisor: Ms Jane Tobias and Dr Daniel Boakye
University of the West of Scotland
Austin Journal of Radiology is an open access, peer review journal publishing original research & review articles in all the fields of Radiology. Austin Journal of Radiology provides a new platform for all radiologists, researchers, scientists, scholars, academicians to publish and find latest research information & scientific advancements in radiology.
Austin Journal of Radiology is a comprehensive Open Access peer reviewed scientific Journal that covers multidisciplinary fields. We provide limitless access towards our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials), Clinical Images.
Austin Journal of Radiology supports the scientific modernization and enrichment in radiology research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed scientific journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinarFight Colorectal Cancer
Don’t miss our recap webinar from the American Society of Clinical Oncology Annual Conference (ASCO) where we discuss the latest research and treatments for colorectal cancer patients presented during the conference.
Dr. Dustin Deming, a medical oncologist and Fight CRC Medical Advisory Board Member will guide us through his findings. Dr. Deming brings a unique perspective as a researcher, oncologist and colorectal cancer survivor. In this webinar we will dive into the research and explain what it means for those living with colorectal cancer.
This is a general overview of options available to patients with liver dominant metastatic disease as well other focal areas of disease which may benefit from services provided by an interventional radiologist
Author: Dr Christa Maria Joel
Module: Effects of lifestyle on health
Supervisor: Ms Jane Tobias and Dr Daniel Boakye
University of the West of Scotland
Austin Journal of Radiology is an open access, peer review journal publishing original research & review articles in all the fields of Radiology. Austin Journal of Radiology provides a new platform for all radiologists, researchers, scientists, scholars, academicians to publish and find latest research information & scientific advancements in radiology.
Austin Journal of Radiology is a comprehensive Open Access peer reviewed scientific Journal that covers multidisciplinary fields. We provide limitless access towards our literature hub with colossal range of articles. The journal aims to publish high quality varied article types such as Research, Review, Short Communications, Case Reports, Perspectives (Editorials), Clinical Images.
Austin Journal of Radiology supports the scientific modernization and enrichment in radiology research community by magnifying access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed scientific journals under one roof thereby promoting knowledge sharing, collaborative and promotion of multidisciplinary science.
2017 ASCO RECAP: The Latest in Colorectal Cancer Research #CRCWebinarFight Colorectal Cancer
Don’t miss our recap webinar from the American Society of Clinical Oncology Annual Conference (ASCO) where we discuss the latest research and treatments for colorectal cancer patients presented during the conference.
Dr. Dustin Deming, a medical oncologist and Fight CRC Medical Advisory Board Member will guide us through his findings. Dr. Deming brings a unique perspective as a researcher, oncologist and colorectal cancer survivor. In this webinar we will dive into the research and explain what it means for those living with colorectal cancer.
This is a general overview of options available to patients with liver dominant metastatic disease as well other focal areas of disease which may benefit from services provided by an interventional radiologist
discusses in detail about approach and management of HCC. Other liver masses and abscesses including cholangiocarcinoma. liver abscess, Hydatid cyst, Hepatic adenoma, hemangioma, Focal Nodular Hyperplasia.
Adjuvant therapy protocols for liver cancer in patients undergoing liver tran...hr77
Many patients undergo liver transplantation for a liver cancer in a setting of liver cirrhosis. When is it possible to consider chemotherapy in such patients? Is it even possible? Is there a role?
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
2. • Hepatocellular carcinoma (HCC) is a primary
malignancy of the liver.
• It is now the third leading cause of cancer deaths
worldwide, with over 500,000 people affected.
• Hepatitis and excessive alcohol are the leading causes
of HCC.
• (Hepatitis B or hepatitis C, 20%) or with cirrhosis (about
80%).
• HCC may present with right upper quadrant pain,
weight loss, jaundice, bloating from ascites, and signs
of decompensated liver disease.
3. • Microscopically, there are four cytological
types:
– fibrolamellar,
– pseudoglandular (adenoid),
– pleomorphic (giant cell) and
– clear cell.
• Local expansion, intrahepatic spread, and
distant metastases.
• Serum AFP rise in 40-64%.
• On CT, HCC can have three distinct patterns of growth:
– A single large tumor
– Multiple tumors
– Poorly defined tumor with an infiltrative growth pattern
4.
5. Diagnostic Procedures
• In patients with lesions less than 1 cm, >>>>
conservative management with close follow-up
and no biopsy is recommended.
• In patients with 1- to 2-cm lesions, a biopsy
should be performed,.
• Patients with lesions greater than 2 cm, cirrhosis,
characteristic imaging studies, and elevated AFP
values can be managed without biopsy.
• Patients with large tumors who are not
candidates for resection or transplantation,
>>>>>> biopsy is frequently not indicated.
• Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and
treatment of hepatocellular carcinoma. Liver Transpl. Feb 2004;10(2 Suppl
1):S115-20.
6. • Important features that guide
treatment include: -
– Size
– Spread (stage)
– Involvement of liver vessels
– Presence of a tumor capsule
– Presence of extrahepatic metastases
– Vascularity of the tumor
8. Child-Pugh score
• The Child-Pugh score is used to assess the
prognosis of chronic liver disease, mainly cirrhosis.
To determine treatment required and the necessity
of liver transplantation.
• The score employs five clinical measures of liver
disease. Each measure is scored 1-3, with 3 indicating
most severe derangement.
9. Chronic liver disease is classified into
Child-Pugh class A to C, employing the
added score from above.
11. • There is no agreement on a common
treatment strategy for patients with HCC
worldwide, and several proposals have
been published.The three major curative
therapies, resection, liver transplantation
and percutaneous treatments, compete
as first-line treatment option for small
single HCC in patients with well-preserved
liver function.
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet
2003; 362: 1907–17.
• Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for
hepatocellular carcinoma: a critical review from the surgeon's perspective.
12. Surgery: Resection and Transplantation
• Surgery is the mainstay of HCC treatment and achieve the best
outcomes in well-selected candidates.
• Less than 5% patients resectable
• Factors affecting resectability:
– Size<5cm
– number of tumors
– involvement of major structures
– hepatic function
– no extra-hepatic spread
– no portal hypertension ·
• Requires experienced surgical and supporting team ·
• 5 year survival 60%-70% ·
• 3 year recurrence 45 - 60%
Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus
transplantation. Hepatology 1999; 30: 1434–40.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients
with cirrhosis. N Engl J Med 1996; 334: 693–9.
13. Transplantation
• Milan Criteria :
Single HCC ≤5 cm or
Up to three nodules ≤3 cm
No extra hepatic spread
• About 10 % qualify for listing
• The major drawback of transplantation is
The scarcity of donors.
The long waiting time.
While Waiting :
Adjuvant therapies whilst on the waiting list are used
in most centers to prevent tumor progression.
14. Resection Vs Transplantaion
• 138 pt with cirrhosis and HCC
• 85 LT and 53 Resection
• Child’s A and B
Liver
Transplantation
Resection
1, 3, 5-year Survival 84, 74, 62 % 83, 57, 50 %
1, 3, 5-year Disease
free
83, 72, 60 % 70, 44, 31 %
Liovet hepatology 1999
15. Percutaneous Treatments
• For patients who cannot undergo resection.
• Complete responses in more than 80% of tumors smaller than 3
cm in diameter, but in 50% of tumors of 3-5 cm in size.
• 5-year survival rates of 40%-60%. reported in patients with small
single tumors, commonly <2 cm in diameter.
• Although these treatments provide good results, they are unable to
achieve response rates and outcomes comparable with surgical
treatments.
• Transarterial Embolization and Chemoembolization is
recommended as first line non-curative therapy for non-surgical
patients with large/multifocal HCC who do not have vascular
invasion or extrahepatic spread.
• Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts
survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352–60.
• Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in
patients with cirrhosis: long-term results of percutaneous image-guided
radiofrequency ablation. Radiology 2005; 234: 961–7.
• Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma
by percutaneous tumor ablation methods: ethanol injection therapy and
radiofrequency ablation. Gastroenterology 2004; 127: S159–66.
16. Percutaneous Ethanol Injection
• 207 patients with cirrhosis + HCC <
5 cm ·
• 100% Ethanol
• Follow up was 25 months
• No complications
• 4.3 sessions per patient
• 88% complete necrosis
• 1 ,2,3-year survival rates:
90,80,63%
Cancer 1992;69:925
19. PEI RFA
Complete
Necrosis
88 % 96 %
Progression
(3ys)
40,4% 15,3 %
Survival
(3ys)
57,6 % 71,1 %
RFA (52) PEI (60)
Complete
Necrosis
47 (90%) 48 (80 %)
Mean No.
of Sessions
1,2 4,8
RFA : More expensive, more complication, more seeding.
PEI: More Sessions, less effective in tumors 2cm
Lin et al. 2004
Radiology 1999; 210:655
20. Palliative Therapies
• Primary treatment for unresectable HCC.
• Embolization agents – usually gelatin or microspheres – may be
administered together with selective intra-arterial chemotherapy
mixed with lipiodol (chemoembolization).
• Doxorubicin, mitomycin and cisplatin are the commonly used
antitumoral drugs.
• Arterial embolization achieves partial responses in 15-55% of
patients, and significantly delays tumour progression and vascular
invasion.
# Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma.
Gastroenterology 2004; 127: S179–88.
# Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation
versus symptomatic treatment in patients with unresectable hepatocellular
carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–9.
# Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol
chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;
35: 1164–71.
21. Transarterial Chemoembolization
Meta-analysis of 7 randomized controlled
trials
• 2 yr survival: 41% (19-63%)
• Treatment response: 35% (16-61%)
• Average no. of sessions: 1-4.5
• Risks:
– Infection
– Tumor lysis syndrome
– Hepatic failure
• Llovel J He aloI2003"37:429
22. Systemic Treatments
• A meta-analysis of seven RCTs comparing tamoxifen vs.
conservative management, comprising 898 patients, showed
neither antitumoral effect nor survival benefit of tamoxifen.
Thus, this treatment is discouraged in advanced HCC.
• Systemic chemotherapy has been tested in nine RCT. The
most active agents in vitro and in vivo are doxorubicin and
cisplatin. Systemic doxorubicin has been tested in more than
1000 patients within clinical trials and provides partial
responses in around 10% of cases, without any evidence of
survival advantages .
• Llovet JM, Bruix J. Systematic review of randomized trials for
unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 2003; 37: 429–42.
• # Fong Y, Kemeny N, Lawrence T. Cancer of the liver and biliary tree. In:
De Vita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and
Practices of Oncology. Philadelphia, USA: Lippincott Williams and
Wilkins, 2001: 1162–204.
• # Palmer D, Hussain S, Johnson P. Systemic therapies for hepatocellular
carcinoma. Expert Opin Investig Drugs 2004; 13: 1555–68.
23. Chemotherapy
• Palliative not Curative.
• Regional (Intra-arterial) better that
systemic.
• Resistant to many agents.
24. Follow-up
• Despite optimal treatment, hepatocellular
carcinoma continues to have a high recurrence
rate. majority of which occur within 2 years.
• Early recurrence after resection is associated
with a dismal prognosis, reducing 5-year survival
rates from 70% to 30%.
• Common extrahepatic sites of metastatic
disease include lung, bone, CNS, and adrenal
glands.
• Factors that increase the likelihood of recurrence
include the presence of :
– multiple foci of hepatocellular carcinoma,
– liver capsule invasion,
– tumor size (>5 cm).
– Vascular invasion, both microscopic and macroscopic.
25. • In general, a CT scan at 1 month
postresection.
• Serum alpha-fetoprotein measurements
and repeat imaging studies (eg, ultrasound,
CT, MRI) every 3-6 months.
• After 2-3 years, safe to increase the follow-
up interval.
27. Summary
• Early-stage hepatocellular carcinoma is typically clinically silent,
and HCC is often advanced at first manifestation.
• Without treatment, the 5-year survival rate is less than 5%.
• Complete surgical resection followed by hepatic transplantation
offers the best long-term survival, but few patients are eligible for
this therapy.
• Radiofrequency ablation is the preferred method for managing
unresectable small HCCs that are few in number. More
widespread disease is treated with percutaneous therapies such
as chemoembolization.
• Systemic administration of biologic and chemotherapeutic agents
is minimally successful in slowing the growth of HCC and typically
is used to control symptoms in patients with overwhelming
disease.
• A multidisciplinary approach that includes surgery, systemic
therapy, and radiation therapy and that is based on the
cooperation of radiation oncologists, interventional and diagnostic
radiologists, hepatologists, and pathologists offer the best chance
Editor's Notes
The International Union Against Cancer or UICC (French: Union Internationale Contre le Cancer)
The American Joint Committee on Cancer (AJCC)
The Model for End-Stage Liver Disease, or MELD, is a scoring system for assessing the severity of chronic liver disease. It was initially developed to predict death within three months of surgery in patients that had undergone a transjugular intrahepatic portosystemic shunt (TIPS) procedure.[1]It uses the patient&apos;s values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. This score is also used by the United Network for Organ Sharing (UNOS) and Eurotransplant for prioritizing allocation of liver transplants. It is calculated according to the following formula:MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43Caveats with the score include:[citation needed]The maximum score given for MELD is 40. All values higher than 40 are given a score of 40If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is used).Patients with a diagnosis of liver cancer will be assigned a MELD score based on how advanced the cancer is. This staging system is known as the TNM system. T stands for the local extent of the tumor, N stands for the presence or absence of lymph node metastases, and M stands for the presence or absence of distant metastasis (tumor spread to another organ such as the lung in the case of liver cancer).